Price negotiation and pricing of anticancer drugs in China: An observational study.

ABSTRACT:

Background

While China has implemented reimbursement-linked drug price negotiation annually since 2017, emphasizing value-based pricing to achieve a value-based strategic purchase of medical insurance, whether drug prices became better aligned with clinical value after price negotiation has not been sufficiently established. This study aimed to assess the changes in prices and their relationship with the clinical value of anticancer drugs after the implementation of price negotiations in China.

Methods and findings

In this observational study, anticancer drug indications that were negotiated successfully between 2017 and 2022 were identified through National Reimbursement Drug Lists (NRDL) of China. We excluded extensions of indications for drugs already listed in the NRDL,

SUBMITTER: Zhou J 

PROVIDER: S-EPMC10793910 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature